volume 37, issue 4, P252-258 2015
DOI: 10.1016/j.bjhh.2015.03.014
View full text
|
Sign up to set email alerts
|
Share

Abstract: Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative bone marrow, dysplasia of the cellular hemopoietic elements and ineffective erythropoiesis. Anemia is a common finding in myelodysplastic syndrome patients, and blood transfusions are the only therapeutic option in approximately 40% of cases. The most serious side effect of regular blood transfusion is iron overload.Currently, cardiovas…

Expand abstract